What the research says about CBG, inflammation, and bacteria

Reading the grades. The ladder has six rungs: the six-rung evidence ladder. Not supported is reserved for a question that has been tested and has come back against the claim. An untested question, one with no primary study in our registry, gets No primary evidence / catalogue in progress instead, which marks a gap in coverage and sits off the ladder. Effects are credited to the study that reported them, limits attached, because for CBG, inflammation and bacteria there is no human study at all in our registry: both findings below are preclinical, one in mice and one in a lab dish.

The short answer

Strip away the chatter and the file on CBG, inflammation and bacteria holds two laboratory studies, both preclinical.

• CBG reduced several signs of intestinal inflammation in a mouse model of colitis (Borrelli 2013).
• Tested in a lab dish (in vitro) alongside several other cannabinoids, CBG showed antibacterial activity against MRSA (Appendino 2008).

Between them, those two studies are close to the whole evidence base for both topics. Neither was done in humans, and neither shows that CBG treats inflammation, inflammatory bowel disease or any infection in people. No CBG product treats any condition. For a brand, that settles the label question: neither study supports an anti-inflammatory or antibacterial claim. Everything past those two findings is unestablished and remains a catalogue in progress.

Evidence grade: Emerging · preclinical only. None of this is medical advice, and CBG is no substitute for medical care.

CBG and inflammation: one mouse study

Take the mice first: a single preclinical study, an anti-inflammatory signal, and no benefit shown in people.

In 2013, Borrelli and colleagues reported that CBG reduced several markers of inflammation in a mouse model of colitis, a chemically induced inflammation of the intestine. Measures of inflammation and immune-cell activity fell in the animals' gut tissue, and the authors themselves described the result as an experimental, preclinical finding.

Early animal results like this one can justify more research, but they cannot establish a use.

Mice differ from people, and a chemically induced colitis model differs from human inflammatory bowel disease, so the study stops well short of showing that CBG treats, cures or eases inflammation, colitis, Crohn's disease, ulcerative colitis or any digestive condition in humans. Our registry holds no human trial of CBG for inflammation of any kind.

• Source: Borrelli et al., 2013, Biochemical Pharmacology (DNBS-induced colitis in mice) · PMID 23415610.
• Evidence grade: Emerging · preclinical (animal model).
• In humans: No primary evidence. Our registry's human record on CBG and inflammation is empty.

CBG, bacteria and MRSA: one lab-dish study

The bacteria story is thinner still, because it never left the dish.

In 2008, Appendino and colleagues reported that several cannabinoids, CBG among them, were active against strains of MRSA (methicillin-resistant Staphylococcus aureus) in vitro. The bacteria were growing in laboratory culture, outside any living body.

An in vitro (test-tube or lab-dish) finding like that is a starting point and little more. Plenty of substances kill or slow bacteria in a dish and then prove useless in a living person, or cause harm. In vitro activity gives research a place to start; it gives a patient nothing to act on.

Nor is it evidence that CBG is an antibiotic, that it can treat or prevent MRSA or any other infection, or that it works against bacteria inside the human body. Do not use CBG to treat an infection. Infections can turn dangerous quickly, MRSA especially, and they need proper medical care.

• Source: Appendino et al., 2008, Journal of Natural Products (minimum-inhibitory-concentration testing against MRSA strains) · PMID 18681481.
• Evidence grade: Emerging · preclinical (in vitro).
• In humans: No primary evidence. CBG has not been tested as a treatment for infection in animals or people.

A note on numbers. Both studies report laboratory potency figures, and they stay in the papers. A potency figure from a dish or a mouse is easily read as a "dose" or a "strength," which would mislead; researchers will find the quantitative data in the primary papers cited with each study.

What the findings do not mean

So much for what the two studies found. The more useful list, for anyone deciding what goes on a label or into a basket, is where they stop:

• Digestive disease. CBG has not been shown to treat or cure any digestive disease, IBD, Crohn's, ulcerative colitis and colitis included. The inflammation evidence is a single mouse study.
• CBG is not an antibiotic. Activity against MRSA in a lab dish does not make a medicine, and gives no reason to reach for CBG against any infection.
• "Anti-inflammatory in people" has not been shown. Our registry holds no human study of CBG and inflammation, and the step from mouse to person is exactly where the record runs out.
• Safety for these uses is unknown, at any amount.
• Do not self-treat, and do not delay or replace medical care. Inflammatory bowel disease and infections can be serious. Anyone managing a condition should work with a clinician and stay on prescribed treatment rather than stopping it to try CBG.
• Blood-pressure caution. Laboratory studies indicate CBG acts on α₂-adrenoceptors, part of the system that helps regulate blood pressure (Cascio 2010). If you take cardiovascular medication, or have a heart or blood-pressure condition, talk to a clinician or pharmacist before using CBG. (This is a general caution, not a numeric claim.)

Reading a record this thin

One mouse study and one lab-dish study make a thin file, and a thin file tempts people to stretch it. Two habits keep it the right size:

1. Credit each finding to its study. "In a 2013 mouse study, CBG reduced signs of colitis" is accurate. "Anti-inflammatory" on its own borrows a benefit the science has not earned, and CBG Atlas neither adopts nor endorses either finding as a claim of its own. 2. Call a gap a gap. Apart from Borrelli 2013 and Appendino 2008, our registry holds no human research on CBG for inflammation or infection, so everything else carries No primary evidence, catalogue in progress: an absence in the record rather than a verdict against the claim.

When controlled human trials are published, they will be graded and added. Until then we stay conservative.

Peregrine Biopharma funds the platform and holds no editorial authority.

Common questions